CLDN18.2 (AA 28-76) protein (His tag)

Produktnummer ABIN8056939

Dieses Recombinant CLDN18.2-Protein wird in Escherichia coli (E. coli) exprimiert.

Kurzübersicht für CLDN18.2 (AA 28-76) protein (His tag) (ABIN8056939)

Target: CLDN18.2

Protein-Typ: Recombinant

Spezies: Human

Quelle: Escherichia coli (E. coli)

Reinheit: > 95 % as determined by reducing SDS-PAGE.

Produktdetails

Proteineigenschaft: AA 28-76

Aufreinigungstag / Konjugat: His tag

Verwendungszweck: Recombinant Human CLDN18.2/Claudin-18 A2 Protein (His Tag)

Sequenz: Asp28-Leu76

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Not validated for activity

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Supplied as a 0.2 μm filtered solution of 25 mM Tris-HCl, 25 mM NaCl, 0.1 % Triton X-100, 10 % glycerol, 0.1 mM GSH, 0.01 mM GSSG, pH 8.0.

Lagerung: -20 °C

Informationen zur Lagerung: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Haltbarkeit: 6 months

Antigendetails

Target: CLDN18.2

Hintergrund: CLDN18,Claudin-18,Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.

Molekulargewicht:

Calculated MW: 19.7 kDa

Observed MW: 18 kDa

Gen-ID: 51208

UniProt: P56856